References
- Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. J Clin Oncol. 2016. DOI:10.1038/nrd.2016.199
- Xiang D, Shigdar S, Qiao G, et al. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics. 2015;5:23–42.
- Heo K, Min SW, Sung HJ, et al. An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies. J Control Release. 2016;229:1–9.
- Chen L, Rashid F, Shah A, et al. The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation. Proc Natl Acad Sci U S A. 2015;112:10002–10007.
- Madsen JB, Andersen LM, Dupont DM, et al. An RNA aptamer inhibits a mutation-induced inactivating misfolding of a serpin. Cell Chem Biol. 2016;23:700–708.
- Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–1982.
- Prodeus A, Abdul-Wahid A, Fischer NW, et al. Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers. Mol Ther Nucleic Acids. 2015;4:e237.
- Hervas-Stubbs S, Soldevilla MM, Villanueva H, et al. Identification of TIM3 2ʹ-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy. Oncotarget. 2016;7:4522–4530.
- Khedri M, Rafatpanah H, Abnous K, et al. Cancer immunotherapy via nucleic acidaptamers. Int Immunopharmacol. 2015;29:926–936.
- Hirota M, Murakami I, Ishikawa Y, et al. Chemically modified interleukin-6 aptamerinhibits development of collagen-induced arthritis in cynomolgus monkeys. Nucleic Acid Ther. 2016;26:10–19.
- Alves Ferreira-Bravo I, Cozens C, Holliger P, et al. Selection of 2ʹ-deoxy-2ʹ-fluoroarabinonucleotide (FANA) aptamers that bind hiv-1 reverse transcriptase with picomolar affinity. Nucleic Acids Res. 2015;43:9587–9599.
- Kuwahara M, Obika S. In vitro selection of BNA(LNA) aptamers. Artif DNA PNA XNA. 2013;4:39–48.
- Chen T, Hongdilokkul N, Liu Z, et al. Evolution of thermophilic DNA polymerases for the recognition and amplification of C2ʹ-modified DNA. Nat Chem. 2016;8:556–562.
- Masaki Y, Ito H, Oda Y, et al. Enzymatic synthesis and reverse transcription of RNAs incorporating 2ʹ-O-carbamoyl uridine triphosphate. Chem Commun. 2016;52:12889–12892. DOI:10.1039/c6cc05796a
- Nagpal M, Nagpal K, Nagpal PN. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (macugen), ranibizumab (lucentis) and bevacizumab (avastin). Indian J Ophthalmol. 2007;55:437–439.
- Lee JH, Canny MD, de Erkenez A, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A. 2005;102:18902–18907.
- Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-vegf antibody in vitro. Angiogenesis. 2004;7:335–345.
- Masaki Y, Miyasaka R, Ohkubo A, et al. Linear relationship between deformability and thermal stability of 2ʹ-O-modified RNA hetero duplexes. J Phys Chem B. 2010;114:2517–2524.
- Tolle F, Brandle GM, Matzner D, et al. A versatile approach towards nucleobase-modified aptamers. Angewandte Chemie. 2015;54:10971–10974.
- Csordas AT, Jorgensen A, Wang J, et al. High-throughput discovery of aptamers for sandwich assays. Anal Chem. 2016;88:10842–10847.
- Ganson NJ, Povsic TJ, Sullenger BA, et al. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a pegylated RNA aptamer. J Allergy Clin Immunol. 2016;137:1610–1613.
- Schlapschy M, Binder U, Borger C, et al. Pasylation: a biological alternative to pegylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng Des Sel. 2013;26:489–501.